Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelyrin Inc (NQ: SLRN )

5.900 -0.050 (-0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Acelyrin Inc

< Previous 1 2 Next >
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
Via Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
Via Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
Via Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Acelyrin
Via Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in  
Via Benzinga
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript
SLRN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Why Acelyrin Stock Plummeted 59% This Week
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate. 
Via The Motley Fool
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
Despite Trial Setback For Acelyrin's Lead Program, Analyst Shows Optimism
Acelyrin Inc (NASDAQ: SLRN) announced topline results from Part B of a Phase 2b/3 trial evaluating izokibep for moderate-to-severe Hidradenitis Suppurativa (HS).  
Via Benzinga
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded up 0.11% to 34,702.55 while the NASDAQ fell 0.86% to 13,797.73.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
Dow Turns Higher; Oracle Shares Tumble After Q1 Results
U.S. stocks traded mixed midway through trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.22% to 34,740.15 while the NASDAQ fell 0.55% to 13,841.02. The S&P 500, also fell,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
A competitor's clinical trial stumble may be benefiting MoonLake. 
Via The Motley Fool
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
Benzinga 
Via Benzinga
Is American Battery Technology Company (ABML) Stock Really Up 1,300%?
American Battery Technology Company (ABML) stock surprised investors Tuesday morning when it appeared to rocketing more than 1,300% higher. 
Via InvestorPlace
Dow Falls 75 Points; US Small Business Optimism Drops In August
U.S. stocks traded lower this morning, with the Dow Jones falling around 75 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.22% to 34,587.58 while the NASDAQ fell 0.21%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Datasea (DTSS) Stock Down 39% Today?
Datasea (DTSS) stock is falling on Tuesday after the company announced a proposed public stock offering priced at 40 cents per share. 
Via InvestorPlace
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
The companies are both working on treatments for a rare skin disease. 
Via Investor's Business Daily
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.